The goal in demanding the introduction of the mechanism was that multiple companies would immediately trigger independent reviews with US Government support, draw attention to problems in decision-making, essentially overwhelm the system, and force further reform discussions. None of this happened, the US Government quickly lost confidence in the industry, and the Australian Government more successfully leveraged the agreement outcome.
Why the failure of a hard-won process reveals so much about an intractable problem
January 16, 2024 Latest NewsBioPharmaNews of the Day
Latest Video
New Stories
-
Prescient secures EU orphan status for PTX-100 for cutaneous T-cell lymphomas
November 19, 2025 - - Australian Biotech -
BCAL advances early cancer detection portfolio as Australian launch looms
November 19, 2025 - - Australian Biotech -
Is this disconnect so entrenched we can no longer recognise the presence of a problem?
November 19, 2025 - - Latest News -
Minister managing the 'double-whammy' of participant and plan growth
November 19, 2025 - - Latest News -
Tryp advances psilocin trial for binge eating disorder as second patient enrolled
November 18, 2025 - - Australian Biotech -
Nyrada advances toward Phase 2a trial of cardioprotective candidate
November 18, 2025 - - Australian Biotech -
We know they're planning something on these issues, because they told us
November 18, 2025 - - Latest News